The stock of TESARO Inc (NASDAQ:TSRO) reached all time high today, Nov, 8 and still has $172.38 target or 35.00% above today’s $127.69 share price. This indicates more upside for the $6.78 billion company. This technical setup was reported by Barchart.com. If the $172.38 PT is reached, the company will be worth $2.37B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 337,939 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 180.75% since April 5, 2016 and is uptrending. It has outperformed by 178.79% the S&P500.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of TESARO Inc (NASDAQ:TSRO) earned “Outperform” rating by Robert W. Baird on Tuesday, July 19. On Monday, October 10 the stock rating was maintained by Leerink Swann with “Outperform”. RBC Capital Markets maintained the shares of TSRO in a report on Monday, October 10 with “Outperform” rating. The stock has “Outperform” rating given by Wells Fargo on Friday, December 4. The rating was maintained by Lake Street with “Buy” on Monday, November 7. On Friday, August 5 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Outperform” rating given on Monday, August 24 by Leerink Swann. The stock of TESARO Inc (NASDAQ:TSRO) earned “Outperform” rating by Wedbush on Monday, October 10. As per Friday, November 4, the company rating was downgraded by Raymond James. The firm earned “Outperform” rating on Friday, November 4 by FBR Capital.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in 2016 Q2. Its up 0.32, from 1.23 in 2016Q1. The ratio improved, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Smith Asset Mgmt Limited Partnership has 4,830 shares for 0.01% of their US portfolio. Mutual Of America Management Ltd Liability holds 0.07% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 39,320 shares. Raymond James Financial Advisors has 0% invested in the company for 5,640 shares. Pictet Asset Management Limited owns 418,730 shares or 0.08% of their US portfolio. Parametrica Management Limited has 1.76% invested in the company for 13,988 shares. Raymond James And accumulated 11,062 shares or 0% of the stock. Cim Investment Mangement Incorporated last reported 3,530 shares in the company. Venbio Select Advisor Ltd Liability reported 514,000 shares or 9.6% of all its holdings. Moreover, Nationwide Fund Advsr has 0.01% invested in TESARO Inc (NASDAQ:TSRO) for 24,235 shares. The Massachusetts-based Capital Impact has invested 0.27% in TESARO Inc (NASDAQ:TSRO). Arrowpoint Asset Mgmt Ltd last reported 30,256 shares in the company. Manufacturers Life Insurance The holds 0% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 17,358 shares. D E Shaw And holds 187,198 shares or 0.03% of its portfolio. Cormorant Asset Mngmt Limited Com has 362,875 shares for 4.33% of their US portfolio. Credit Suisse Ag holds 0.01% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 66,035 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 6 sales for $4.43 million net activity. Hanke Jeffrey H. sold $2.51M worth of stock or 29,166 shares. The insider Huber Martin H. Jr. sold 327 shares worth $39,662. English Edward C sold 7,000 shares worth $285,274.
More recent TESARO Inc (NASDAQ:TSRO) news were published by: Fool.com which released: “Why Tesaro, Inc. Is Skyrocketing 20% Today” on October 10, 2016. Also Investorplace.com published the news titled: “Tesaro Inc (TSRO) Soars on Trial Data, Analyst Upgrades” on October 10, 2016. Investorplace.com‘s news article titled: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” with publication date: October 10, 2016 was also an interesting one.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.